Price
No data yet.
Social Signal Score
Revenue
$5.58M+78520.65%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Aras Azadian Mba
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 112
- Beta
- 0.33
- Country
- CA
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -4.84
Financials
Revenue
$5.58M+78520.7%Net Income
$-160.8KEBITDA
$278.5KFree Cash Flow
$-709.5KEPS (diluted)
$0.00Shares Outstanding (diluted)
134.79M+1257.8%Operating Expenses
$2.93MCash & Debt
$151.8KReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $25.46M | $-2.84M | $-0.02 |
| 2024 | $25.46M | $-3.62M | $-0.04 |
| 2023 | $16.79M | $-8.74M | $-0.10 |
| 2022 | $4.05M | $-14.74M | $-0.25 |
| 2021 | $3.27M | $-16.77M | $-0.41 |
| 2020 | $1.57M | $-32.86M | $-1.12 |
| 2019 | $168.3K | $-21.07M | $-1.05 |
| 2018 | $118.0K | $-7.10M | $-0.45 |
| 2017 | $26.7K | $-2.60M | $-0.19 |
| 2016 | $0.00 | $-29.8K | $-0.00 |
Valuation
AVCNFhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80-20.00%Social Signal Score
Mentions (8)
- Newsglobenewswire.com·10d ago·Negative
… MyMedi.ca sales, up from 19%; QUIX™ launches with 10 SKUs TORONTO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQB: AVCNF) (FSE: 0NN), a commercial-stage international biopharmaceutical company focused on cannabinoid-based medicines, today reported financial results for the third quarter ended September 30, 2026. The Company achieved adjusted EBITDA positive $0.22 million, an improvement of $1.01 million from Q3 2025 and $0.58 million from Q2 202…
View source ↗ - Newsglobenewswire.com·20d ago·Neutral
…vicanna to Report Q3 2026 Results and Host Call on Nov. 12 TORONTO, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQB: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products announces November 12, 2026, as the date for reporting Q3 2026 financial results and that management will host a live webcast at 8:30 a.m. ET that morning to present the results, …
View source ↗ - Newsglobenewswire.com·24d ago·Negative
Avicanna Announces Closing of Non-Brokered Private Placement of Non-Convertible Debenture Units NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS
View source ↗ - Newsglobenewswire.com·37d ago·Neutral
Avicanna Transitions US Listing to OTCQB TORONTO, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQB: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products announces that in the US, the Company will transition to OTCQB effective October 16, 2026.
View source ↗ - Newsglobenewswire.com·68d ago·Neutral
Avicanna to Present at a Life Sciences Investor Forum on September 17, 2026 TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”), a commercial-stage international biopharmaceutical company focused on cannabinoid-based medicines, is pleased to announce that Aras Azadian, CEO of Avicanna Inc. and Avicanna Inc. will be presenting live at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on September 17th, 2026.
View source ↗ - Newsglobenewswire.com·74d ago·Neutral
Avicanna Launches MyMedi.ca Integrated Healthcare Program in Canada Integrating MyMedi.ca healthcare provider-guided medical cannabis care into hospitals, specialty clinics, insurers and multidisciplinary healthcare networks in Canada Integrating MyMedi.ca healthcare provider-guided medical cannabis care into hospitals, specialty clinics, insurers and multidisciplinary healthcare networks in Canada
View source ↗ - Newsglobenewswire.com·95d ago·Negative
Avicanna Announces Closing of Strategic Non-Brokered Private Placement Strategic investment by pharmaceutical executive and life sciences investor Michael Porter Strategic investment by pharmaceutical executive and life sciences investor Michael Porter
View source ↗ - Newsglobenewswire.com·100d ago·Negative
Avicanna Reports Q2 2026 Financial Results Gross margin improves to 57%, supported by 48% quarterly growth in proprietary product sales QUIX™ rapid-onset portfolio prepared for Q3 launch with more than 35 commercial listings secured
View source ↗
Earnings
Tue, Apr 6(in 4 months)
Consensus estimate $-0.02 per share
Typical surprise +83.6% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 17$-0.01 vs $-0.03beat
- Wed, May 13$-0.00 vs $-0.03beat
- Mon, Nov 17$-0.01 vs $-0.02beat
- Thu, Aug 14$-0.00 vs $-0.03beat
- Wed, May 14$0.00 vs $-0.04beat
- Wed, Nov 13$-0.01 vs $-0.03beat
Estimates and results for AVCNF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in AVCNF.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
